Replacement mitral valves

Information

  • Patent Grant
  • 11617646
  • Patent Number
    11,617,646
  • Date Filed
    Monday, January 6, 2020
    4 years ago
  • Date Issued
    Tuesday, April 4, 2023
    a year ago
Abstract
A prosthetic mitral valve includes an anchor assembly, an annular strut frame, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly includes a ventricular anchor, an atrial anchor, and a central portion therebetween. The annular strut frame is disposed radially within the anchor assembly. An atrial end of the annular strut frame is attached to the anchor assembly such that a ventricular end of the annular strut frame is spaced away from the anchor assembly.
Description
BACKGROUND

The mitral valve lies between the left atrium and the left ventricle of the heart. Various diseases can affect the function of the mitral valve, including degenerative mitral valve disease and mitral valve prolapse. These diseases can cause mitral stenosis, in which the valve fails to open fully and thereby obstructs blood flow, and/or mitral insufficiency, in which the mitral valve is incompetent and blood flows passively in the wrong direction.


Many patients with heart disease, such as problems with the mitral valve, are intolerant of the trauma associated with open-heart surgery. Age or advanced illness may have impaired the patient's ability to recover from the injury of an open-heart procedure. Additionally, the high costs associated with open-heart surgery and extra-corporeal perfusion can make such procedures prohibitive.


Patients in need of cardiac valve repair or cardiac valve replacement can be served by minimally invasive surgical techniques. In many minimally invasive procedures, small devices are manipulated within the patient's body under visualization from a live imaging source like ultrasound, fluoroscopy, or endoscopy. Minimally invasive cardiac procedures are inherently less traumatic than open procedures and may be performed without extra-corporeal perfusion, which carries a significant risk of procedural complications.


Minimally invasive aortic valve replacement devices, such as the Medtronic Corevalve or the Edwards Sapien, deliver aortic valve prostheses through small tubes which may be positioned within the heart through the aorta via the femoral artery or through the apex of the heart. However, the mitral valve differs from the aortic valve in that the shape and anatomy immediately surrounding the valve varies greatly from one side of the valve to the other. Moreover, current cardiac valve prostheses are not designed to function effectively within the mitral valve. Further, current cardiac valve prostheses delivered via a minimally invasive device are often difficult to place correctly within the native valve, difficult to match in size to the native valve, and difficult to retrieve and replace if initially placed incorrectly.


These and other deficiencies in existing approaches are described herein.


SUMMARY OF THE DISCLOSURE

In general, in one embodiment, a replacement mitral valve includes an anchor assembly including a ventricular anchor, an annular central portion, and an atrial anchor, an annular strut frame disposed radially within the anchor assembly, a central annular member between the anchor assembly and annular strut frame, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor. The central annular member is connected to both the anchor assembly and the annular strut frame so as to connect the anchor assembly to the annular strut frame.


This and other embodiments can include one or more of the following features. A ventricular end of the central annular member can have a smaller diameter than a diameter of the atrial end of the central annular member. The diameter of the ventricular end can be between 25 mm and 30 mm, and the diameter of the atrial end is between 30 mm and 35 mm. The central annular member can include a plurality of linear posts extending from an atrial end to a ventricular end and a plurality of zig-zag circumferential members extending circumferentially therearound. The central annular member can have a lower spring constant than the strut frame. The strut frame can have a higher spring constant than the anchor assembly. The central annular member can include a suspension. The central annular member and the anchor assembly can be connected together with couplers. The central annular member and the annular strut frame can be connected together with couplers. The central annular member can be configured to minimize deformation of replacement leaflet alignment in response to deformation of an expandable anchor. The device can be configured to self-expand from a constrained configuration to an expanded configuration. The device can be configured to foreshorten upon expansion of the atrial anchor, ventricular anchor, and central portion from the constrained configuration to the expanded configuration.


In general, in one embodiment, a replacement mitral valve includes an anchor assembly comprising a ventricular anchor, an annular central portion, and an atrial anchor, an annular strut frame disposed radially within the anchor assembly, a suspension connecting the anchor assembly to the annular strut frame, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor.


This and other embodiments can include one or more of the following features. The suspension can have a lower spring constant than the strut frame. The strut frame can have a higher spring constant than the anchor assembly. The suspension can include a plurality of springs. The springs can be leaf springs. The suspension and the anchor assembly can be connected together with couplers. The suspension and the annular strut frame can be connected together with couplers. The suspension can be configured to minimize deformation of replacement leaflet alignment in response to deformation of an expandable anchor. The device can be configured to self-expand from a constrained configuration to an expanded configuration. The device can be configured to foreshorten upon expansion of the atrial anchor, ventricular anchor, and central portion from the constrained configuration to the expanded configuration.


In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly including an atrial anchor, a ventricular anchor, and a central portion therebetween, and a plurality of replacement leaflets coupled with the anchor assembly. The atrial anchor or the ventricular anchor includes an annular frame having plurality of pear-shaped extensions connected together. The anchor assembly is configured to self-expand from a constrained configuration to an expanded configuration in which the ventricular anchor and the atrial anchor are flared radially outward relative to the central portion. The anchor assembly in the expanded configuration is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor.


This and other embodiments can include one or more of the following features. The annular frame can be substantially circular. The device can be configured to foreshorten upon expansion of the atrial anchor, ventricular anchor, and central portion from the constrained configuration to the expanded configuration. The atrial anchor and the ventricular anchor can each have a diameter in the expanded configuration that is greater than a diameter of the central portion in the expanded configuration. The atrial anchor and the ventricular can include an annular frame having a plurality of pear-shaped extensions connected together. At least two of the plurality of pear-shaped extensions can have different lengths from one another. Each of the plurality of pear-shaped extensions can include an inner rounded portion and an outer rounded portion. The inner rounded portion can have a smaller diameter than a diameter of the outer rounded portion. The diameter of the inner rounded portion can be between 2 mm and 3 mm, and the diameter of the outer rounded portion can be between 5 mm and 6 mm. The atrial anchor, ventricular anchor, and central portion can all be integral with one another. The prosthetic mitral valve can further include an annular strut frame secured radially within the anchor assembly. The annular strut frame can be configured to support the plurality of replacement leaflets. When the anchor assembly is in the expanded configuration, extensions on the ventricular anchor can curve around to point at least partially radially inwards. When the anchor assembly is in the expanded configuration, extensions of the atrial anchor point can be substantially in the atrial direction.


In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly including an atrial anchor, a ventricular anchor, and a central portion therebetween, and a plurality of replacement leaflets coupled with the anchor assembly. The atrial anchor or the ventricular anchor includes an annular frame having plurality of extensions connected together, wherein there are at least two extensions of differing radial lengths. The anchor assembly is configured to self-expand from a constrained configuration to an expanded configuration in which the ventricular anchor and the atrial anchor are flared radially outward relative to the central portion. The anchor assembly in the expanded configuration is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor.


This and other embodiments can include one or more of the following features. The annular frame can be substantially circular. The device can be configured to foreshorten upon expansion of the atrial anchor, ventricular anchor, and central portion from the constrained configuration to the expanded configuration. The atrial anchor and the ventricular anchor can each have a diameter in the expanded configuration that is greater than a diameter of the central portion in the expanded configuration. The atrial anchor or the ventricular anchor can include a plurality of pear-shaped extensions connected together. The atrial anchor, ventricular anchor, and central portion can all be integral with one another. The prosthetic mitral valve can further include an annular strut frame secured radially within the anchor assembly. The annular strut frame can be configured to support the plurality of replacement leaflets. When the anchor assembly is in the expanded configuration, extensions on the ventricular anchor can curve around to point at least partially radially inwards. When the anchor assembly is in the expanded configuration, extensions of the atrial anchor can point substantially in the atrial direction.


At least one extension can have a radial length that is between 1 mm and 3 mm longer than another extension. The plurality of extensions can include a plurality of first extensions having a first radial length and a plurality of second extensions having a second radial length. The first and second extensions can be arranged in an alternating pattern around the annular frame.


In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly including an atrial anchor, a ventricular anchor, and a central portion therebetween, and a plurality of replacement leaflets coupled with the anchor assembly. The ventricular anchor includes an annular frame having plurality of extensions connected together. The anchor assembly is configured to self-expand from a constrained configuration to an expanded configuration in which the ventricular anchor and the atrial anchor are flared radially outward relative to the central portion and ends of the extensions on the ventricular anchor curve around to point at least partially radially inwards. The anchor assembly in the expanded configuration is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor.


This and other embodiments can include one or more of the following features. The annular frame can be substantially circular. The device can be configured to foreshorten upon expansion of the atrial anchor, ventricular anchor, and central portion from the constrained configuration to the expanded configuration. The atrial anchor and the ventricular anchor each have a diameter in the expanded configuration that is greater than a diameter of the central portion in the expanded configuration. The atrial anchor or the ventricular anchor includes a plurality of pear-shaped extensions connected together. The atrial anchor, ventricular anchor, and central portion can all be integral with one another. The prosthetic mitral valve can further include an annular strut frame secured radially within the anchor assembly. The annular strut frame can be configured to support the plurality of replacement leaflets. When the anchor assembly is in the expanded configuration, extensions of the atrial anchor can point substantially in the atrial direction. At least two of the plurality of pear-shaped extensions can have different lengths from one another. A radius of curvature formed by the curved ends of the extensions of the ventricular anchor can be between approximately 0.1″ and 0.2.″


In general in one embodiment, a prosthetic mitral valve includes an anchor assembly including an atrial anchor, a ventricular anchor, and a central portion therebetween, and a plurality of replacement leaflets coupled with the anchor assembly. The atrial anchor includes an annular frame having plurality of extensions connected together. The anchor assembly is configured to self-expand from a constrained configuration to an expanded configuration in which the ventricular anchor and the atrial anchor are flared radially outward relative to the central portion and ends of the extensions on the atrial anchor point substantially in the atrial direction. The anchor assembly in the expanded configuration is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor.


This and other embodiments can include one or more of the following features. The annular frame can be substantially circular. The device can be configured to foreshorten upon expansion of the atrial anchor, ventricular anchor, and central portion from the constrained configuration to the expanded configuration. The atrial anchor and the ventricular anchor can each have a diameter in the expanded configuration that is greater than a diameter of the central portion in the expanded configuration. The atrial anchor or the ventricular anchor can include a plurality of pear-shaped extensions connected together. The atrial anchor, ventricular anchor, and central portion can all be integral with one another. The prosthetic mitral valve can further include an annular strut frame secured radially within the anchor assembly. The annular strut frame can be configured to support the plurality of replacement leaflets. When the anchor assembly is in the expanded configuration, extensions on the ventricular anchor can curve around to point at least partially radially inwards. At least two of the plurality of pear-shaped extensions can have different lengths from one another.


In general, in one embodiment, a replacement mitral valve includes an anchor assembly including a ventricular anchor, an annular central portion, and an atrial anchor, an annular strut frame disposed radially within the anchor assembly, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly is configured to expand from a constrained configuration to an expanded configuration in which the ventricular anchor and the atrial anchor are flared radially outward relative to the central portion. The anchor assembly in the expanded configuration is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor. The annular strut frame is flared radially outward to form a funnel shape on an atrial side of the strut frame.


This and other embodiment can include one or more of the following features. The replacement mitral valve can further include a plurality of ovoid strut attachment mechanisms extending from the annular strut frame. The ovoid strut attachment mechanisms can be configured for sewing attachment of the replacement leaflets. The annular strut frame can be attached to the anchor assembly with a plurality of couplers. The plurality of couplers can be rivets. The annular strut frame can be attached to the anchor assembly through a central annular member. The annular strut frame can be attached to the anchor assembly through a suspension. The atrial anchor can further include a flared atrial portion, wherein the flared atrial portion of the atrial anchor and the flare of the annular strut frame can be configured to substantially conform to one another. The strut frame can flare at an angle of approximately 60-65 degrees relative to a central axis of the mitral valve.


In general, in one embodiment, a replacement mitral valve includes an anchor assembly including a ventricular anchor, an annular central portion, and an atrial anchor, an annular strut frame disposed radially within the anchor assembly, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly is configured to expand from a constrained configuration to an expanded configuration in which the ventricular anchor and the atrial anchor are flared radially outward relative to the central portion. The anchor assembly in the expanded configuration is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor. The annular strut frame has a plurality of rivet holes at a ventricular end of the strut frame configured for attachment to the anchor assembly.


This and other embodiments can include one or more of the following features. The replacement mitral valve can further include a plurality of ovoid strut attachment mechanisms extending from the annular strut frame. The ovoid strut attachment mechanisms can be configured for sewing attachment of the replacement leaflets. The annular strut frame can be attached to the anchor assembly with a plurality of couplers. Each coupler can extend through a hole of the plurality of holes. The plurality of couplers can be rivets. The anchor assembly can further include a plurality of holes. A coupler can extend through each of the holes of the anchor assembly for attachment to the annular strut frame. The annular strut frame can be attached to the anchor assembly through a central annular member. The annular strut frame can be attached to the anchor assembly through a suspension.


In general, in one embodiment, a replacement mitral valve includes an anchor assembly comprising a ventricular anchor, an annular central portion, and an atrial anchor, an annular strut frame disposed radially within the anchor assembly, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly is configured to expand from a constrained configuration to an expanded configuration in which the ventricular anchor and the atrial anchor are flared radially outward relative to the central portion. The anchor assembly in the expanded configuration is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor. The annular strut frame includes a suture extending around an entire circumference of the annular strut frame to prevent flaring of one end of the annular strut frame relative to another during delivery of the replacement valve.


In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly including an atrial anchor, a ventricular anchor, and a central portion therebetween, and a plurality of replacement leaflets coupled with the anchor assembly. The atrial anchor or the ventricular anchor includes an annular frame having plurality of peaks and valleys extending around the circumference. A hook is positioned in one or more of the valleys configured to engage tissue. The anchor assembly is configured to self-expand from a constrained configuration to an expanded configuration in which the ventricular anchor and the atrial anchor are flared radially outward relative to the central portion. The anchor assembly in the expanded configuration is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor.


In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly including an atrial anchor, a ventricular anchor, and a central portion therebetween, and a plurality of replacement leaflets coupled with the anchor assembly. A plurality of hooks extend from the central portion configured to engage tissue. The anchor assembly is configured to self-expand from a constrained configuration to an expanded configuration in which the ventricular anchor and the atrial anchor are flared radially outward relative to the central portion. The anchor assembly in the expanded configuration is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor.





BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:



FIG. 1 shows a portion of an embodiment of a valve prosthesis in an expanded configuration.



FIG. 2 is a side view illustrating the prosthesis of FIG. 1 including leaflets.



FIG. 3 illustrates an integral central portion and ventricular anchor after being cut from a sheet of material.



FIG. 4A is a top view of another embodiment of a valve prosthesis.



FIG. 4B is a side view of another embodiment of a valve prosthesis.



FIG. 4C is a close-up showing two anchor extensions side by side.



FIG. 4D shows a flattened anchor assembly.



FIG. 5 shows another embodiment of a flattened anchor assembly.



FIG. 6A shows another embodiment of a valve prosthesis.



FIG. 6B shows the anchor assembly of the valve prosthesis of FIG. 6A.



FIG. 6C shows a central member of the valve prosthesis of FIG. 6A.



FIG. 6D shows a strut frame of the valve prosthesis of FIG. 6A.



FIG. 6E shows a close-up of the anchor assembly of FIG. 6B.



FIG. 6F shows a side view of the anchor assembly of FIG. 6B.



FIG. 6G is a cross-section of the valve prosthesis of FIG. 6A without the skirt or leaflets attached thereto.



FIG. 7 shows a top view of another embodiment of a valve prosthesis.



FIG. 8 shows an embodiment of a strut frame.



FIG. 9 shows another embodiment of a strut frame.



FIGS. 10A-10D show various view of a strut frame.



FIG. 10E shows the strut frame of FIGS. 10A-10D flattened.



FIGS. 11A-11B shows another embodiment of a valve prosthesis.



FIGS. 12A-12B show another embodiment of a valve prosthesis.



FIGS. 13A-13B show another embodiment of a valve prosthesis.



FIG. 14 shows a top view of a valve prosthesis having spring members between the strut frame and the anchor assembly.



FIGS. 15A-15D show various embodiments of spring members.



FIG. 16A-16C show another embodiment of a valve prosthesis.



FIG. 17A shows another embodiment of a valve prosthesis.



FIG. 17B shows the anchor assembly of the valve prosthesis of FIG. 17A.



FIG. 17C shows the central member of the valve prosthesis of FIG. 17A.



FIG. 17D shows the strut frame of the valve prosthesis of FIG. 17A.



FIG. 18A shows another embodiment of a valve prosthesis.



FIG. 18B shows a flattened strut frame of the valve prosthesis of FIG. 18A.



FIG. 18C shows a flattened anchor assembly of the valve prosthesis of FIG. 18A.



FIGS. 19A-19B shows another embodiment of a valve prosthesis.



FIG. 20A shows a flattened and overlaid anchor assembly and strut frame.



FIG. 20B shows the strut frame of FIG. 20A.



FIG. 20C shows the anchor assembly of FIG. 20A.





DETAILED DESCRIPTION

This disclosure includes replacement heart valves (also referred herein as prosthetic heart valves), methods of manufacturing replacement heart valves, including subassemblies thereof, and methods of using replacement heart valves. This disclosure describes the prostheses in the context of replacement mitral valves, but it is conceivable that the prostheses herein can be used or modified to be used as other replacement heart valves. In some embodiments, the replacement heart valves are self-orienting (at least on one side) replacement mitral valves configured to be delivered using minimally invasive techniques.


The replacement heart valves herein include an expandable anchor that includes an atrial anchor (e.g., configured to be placed on an atrial side of a mitral valve annulus), a ventricular anchor (e.g., configured to be placed on a ventricular side of a mitral valve annulus), and a central portion axially between the atrial and ventricular anchors. The expandable anchor is adapted to be collapsed towards a collapsed delivery configuration, and is adapted to expand towards an expandable configuration. The replacement heart valves also include a plurality of struts or strut frame secured to at least one of the central portion, the ventricular anchor, or the atrial anchor for securing a plurality of replacement leaflets thereto. The struts or strut frame can be considered part of the expandable anchor, and in embodiments herein are configured to deform as the rest of the expandable anchor is collapsed. It may be possible to incorporate struts that are not deformable, but which are still secured to the expandable anchor. These types of struts may not be considered part of the expandable anchor but are secured to the expandable anchor. The struts extend distally, that is, towards the ventricular anchor. In the context of replacement mitral valves, the “distal” end of the replacement valve refers to the end of the replacement valve that is to be positioned on the ventricular side of the annulus, while “proximal” end refers to the end of the replacement valve that is to be positioned on the atrial side of the annulus. “Distally” in the context of trans-atrial delivery can be used to refer to a location closer to the left ventricle than the left atrium, while “proximally” is generally used to refer to a location closer to the left atrium than the left ventricle.


In some embodiments, the expandable anchor is adapted to completely self-expand, and in some embodiments it is configured to be partially self-expanding and partially expand by non-self-expanding influences (e.g., a balloon). The expandable anchors can be made of (or partly made of) a super elastic material such as nitinol.


In methods of use, the prostheses described herein can be delivered to a cardiac valve orifice, such as the mitral valve, by using minimally invasive techniques to access the cardiac valve. Access routes and procedures are known, such as making small incisions in the patient's body and passing the prosthesis through the apex of the heart to, for example, a mitral valve. An additional exemplary access route includes delivering the valve through the venous system and into the left atrium via a transseptal puncture. A transseptal approach can impart size limitations on the delivery and thus the delivery profile of the replacement heart valve. Additionally, a transseptal approach can also impart certain flexibility requirements on the replacement heart valve. The replacement heart valves herein are configured to be collapsed into a delivery configuration so they can fit within a delivery device. The replacement heart valves can be delivered to the treatment site within the delivery device and then deployed from the delivery device. If necessary, the replacement valves can be repositioned, re-sheathed (partially or completely) if necessary, and then re-deployed.


Replacement heart valves herein are configured to be secured in the native valve orifice by sandwiching the cardiac orifice between ventricular and atrial anchors, which are larger in diameter than the valve orifice, and by applying a radial force from the center portion outward against the cardiac orifice. Additional engagement between the prostheses and cardiac tissue can be added with wire hooks extending from the valve prostheses.



FIGS. 1-3 show an exemplary mitral valve prosthesis 10 in an expanded configuration after an expandable anchor and struts have been secured together. The portion of the replacement valve shown in FIG. 1 may be referred to as an anchor subassembly, which includes an expandable anchor 1 and struts 5, but excludes leaflets and any skirts that may be incorporated into the final replacement valve. Expandable anchor 1 includes an atrial anchor 2, a ventricular anchor 4, and a central portion 3 therebetween. In this embodiment, atrial anchor 2 is configured and adapted to be disposed on an atrial side of a mitral valve orifice, and ventricular anchor 4 is configured and adapted to be disposed on a ventricle side of the mitral valve orifice. In some uses, however, expandable anchor 1 may be implanted so that atrial anchor 2 as shown is positioned on the ventricle side and ventricular anchor 4 is positioned on the atrial side. The anchor subassembly and/or struts can be made of wire, such as a metal wire, such as nitinol.


Three struts 5 are secured to the anchor subassembly 1, and in this embodiment are secured to central portion 3, and at least a portion of struts 5 are disposed radially inward relative to central portion 3. Struts 5 are extending, or pointing, towards ventricular anchor 4 and away from atrial anchor 2.


Radially inner surfaces of the expandable anchor and the struts define central opening 6, which is radially within the expandable anchor. The radially inner surfaces of central portion 3 substantially define the perimeter of central opening 6. Replacement leaflets, which are not shown in FIG. 1 for clarity, are secured to struts 5 and are disposed at least partially in central opening 6, and are configured to control blood flow therethrough.


In this embodiment, atrial anchor 2 includes overlapping arches 32 extending around the perimeter of the anchor 2. Ventricular anchor 4 includes a plurality of arches 42 that extend from the central portion towards the ventricular end. A plurality of spaces 49 (see FIG. 3) extend between adjacent arches 42, the configurations and sizes of which are defined by the configuration of adjacent arches 42, are configured to advantageously allow the sub-valvular structures, such as chords, to slide between adjacent arches 42 when the ventricular anchor is expanded on the ventricular side of the mitral valve annulus. The arch 32, 42 tips are rounded, or curved (as opposed to abrupt or sharp) to avoid damaging the tissue when implanted.


In the expanded configuration shown in FIG. 1 (which is also an “as-manufactured” configuration), atrial anchor 2 and ventricular anchor 4 extend radially outward from central portion 3, and are considered to flare outward relative to central portion 4. Atrial anchor 2 and ventricular anchor 4 can also be considered flanged relative to central portion 3. The flared configuration of atrial and ventricular anchors 2 and 4 relative to central portion 3 is described in the context of a side view of the expandable anchor, as can be seen in FIG. 2 (which illustrates leaflets secured to struts).


In some embodiments, one or more of the flared anchors are orthogonal to a longitudinal axis “LA” (illustrated in FIG. 2) passing through central opening 6. In some embodiments, the flared anchor portions have a smooth curve radially outward. In some flared configuration the two anchors and the central portion define a general “C” or “U” shape in a side view of the expandable anchor. A “C” or “U” configuration is not limited to symmetrical configurations, however, as there can be slight deviation from a true “U” and still be considered to be U-shaped. For example, the expandable anchor could define a “C” configuration, but one of the atrial and ventricular anchors could have a tighter curvature than the other anchor. When the anchor portions are flared and create a “C” shaped configuration, the atrial and ventricular anchors are slightly curved inward towards the central portion at their respective ends. In some embodiments, atrial anchor 2 and ventricular anchor 4 are substantially parallel to one another, such as exactly parallel to one another. In some embodiments the configuration of the flared anchors creates a substantially constant radius of curvature (i.e., a semi-circle) so that stress across anchors 2 and 4, and central portion 4 is balanced, thereby reducing fatigue or wear at any one point along the prosthesis. In other embodiments, the flared configuration of the two anchors and the central portion define a general hour-glass shape in a side view of the expandable anchor (see, e.g., FIGS. 6F and 6G). That is, the anchor portions can be flared outwards relative to the central portion and then curved or bent to point at least partially back in the axial direction. Again, an hour glass configuration is not limited to symmetrical configuration.


In some embodiments the expanded anchor 1 (not including the struts) has a length “L” (see FIG. 2, measured from the atrial end to the ventricular end, parallel to the longitudinal axis LA) of 6-12 mm, such as 6-11 mm, 6-10 mm, 6-9 mm, 7-11 mm, 8-10 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, and 12 mm. In some embodiments the length of the expanded prosthesis, including the struts (“LS” as shown in FIG. 2), has a length of 16-20 mm, such as 17-19 mm, 16 mm, 17 mm, 18 mm, 19 mm, and 20 mm with the struts. In some embodiments, the expanded anchor has an expanded diameter (“D” in FIG. 2) of about 35 mm to about 75 mm, such as about 45 mm to about 65 mm. In some of those embodiments the device is configured to be collapsed to a collapsed configuration in which it has a collapsed diameter D of 7 mm to 12 mm (i.e., the prosthesis can be collapsed down to fit within a 21-36 French catheter). In some embodiments the central opening 6 diameter is between 20 mm and 45 mm, such as between 25 mm and 40 mm, such as between 28 mm and 38 mm. In embodiments in which central opening 6 is not a perfect circle, the central opening diameter refers to the greatest linear dimension between points on the central portion, when viewed in an end view such as FIG. 10A.


Referring to FIGS. 4A-4C, in some embodiments, one or both of the atrial and ventricular anchors 2302, 2304 of an expandable anchor of a replacement valve 2300 can include petals or extensions 2322a,b (only two are labeled for clarity) that are pear-shaped. That is, each extension 2322a,b can included two bulbous or rounded portions 2323a, 2323b. The radial innermost rounded portion 2323a can have a greater diameter than the radial outermost portion 2323b. The radial innermost rounded portion 2323a can be approximately 5-6 mm in diameter while the radial outermost portion 2323b can be approximately 2-3 mm in diameter. The pear-shaped extensions 2322a can advantageously provide sufficient grabbing force while providing a large-diameter blunt radial edge to reduce the chances of tissue damage.


Referring still to FIGS. 4A-4C, in some embodiments, the extensions 2322a,b can have varying radial lengths. For example, the anchor can include alternating longer extensions 2322a and shorter extensions 2322b around the circumference. The longer extensions 23222a, for example, can have a length that is 1-3 mm longer than a length of the shorter extensions 2322b. Having varying lengths can advantageously allow the extensions 2322a, 2322b to be cut out of a single tube or piece of material while still providing a large-diameter blunt radial edge. For example, FIG. 4D shows a pattern for the expandable anchor 2301 cut out of a flat piece of material (which would then be rolled to form the anchor 2301). In this pattern 2301, the atrial side includes double hooks therein for attachment to a delivery system, which will be described further below. FIG. 5 shows a similar pattern for an expandable anchor 5301 cut out of a flat piece of material. The expandable anchor 5301 includes alternating pear-shaped extensions only on the ventricular side of the anchor 5301.


In some embodiments where the alternating pear-shaped extensions are only on the ventricular side, the atrial side can include overlapping extensions that are substantially semicircular in shape, as shown in FIGS. 2 and 7. In other embodiments, the anchor with the pear-shaped extensions can be used on both the ventricular and atrial side. In yet other embodiments, the anchor with the pear-shaped extensions can be used only on the atrial side. Moreover in some embodiments, the pear-shaped extensions can be arranged in an overlapping fashion.



FIGS. 6A-6G show another embodiment of a replacement valve 3200 including an atrial anchor 3202 and ventricular anchor 3204. The atrial and ventricular anchors 3202 extend radially outwards relative to the central portion 3203. The extensions 3222a,b of the atrial anchor and of the distal anchor are both pear-shaped and of alternating lengths, as described above with respect to valve 2300. Further, the expandable anchor 3201 (including atrial anchor 2302, ventricular anchor 3204, and central portion 3203) forms a substantially hour-glass shape when viewed from the side, as can best be seen in FIGS. 6F and 6G). Referring to FIG. 6G, the atrial anchor 3202 extends radially outwards at an angle α (relative an axis 3297 parallel to an axis of the plane of the annulus (perpendicular to the central longitudinal axis 3299)) of between 20 and 30 degrees, such as approximately 25 degrees. The tips of extensions 3222a,b of the atrial anchor are then bent or curved such that they point substantially in the atrial direction when implanted. Likewise, the ventricular anchor 3204 extends radially outwards at an angle B (relative an axis 3298 parallel to an axis of the plane of the annulus (perpendicular to the central longitudinal axis 3299)) of between 5 and 20 degrees, such as approximately 10 degrees. Further, the tips of extensions 3222b of the ventricular anchor are bent or curved such that they point at least partially in the ventricular direction. Moreover, the tips of the ventricular anchor 3222b continue curving at least partially radially inwards. The radius of curvature R of the tips of the ventricular anchor 3204 can be approximately 0.1 inches to 0.2 inches, such as ⅛ inches. Having the tips extensions 3222b of the ventricular anchor 3204 curve around to point radially inwards advantageously keeps the tips from getting caught on material, such as cords, in the ventricle during implantation. Further, having the tips extensions 3222a of the atrial anchor point substantially in the atrial direction advantageously provides a funnel to enhance flow of blood from the atrium to the ventricle (i.e., without interrupting the flow or providing pockets for the blood to pool therein).


In some embodiments, one or more of the anchors can have holes, eyelets, or other attachments mechanisms therein to allow a delivery device to attach thereto to control placement of the replacement valve. Exemplary delivery devices and methods are described in International Patent Application filed May 13, 2016, titled “CARDIAC VALVE DELIVERY DEVICES AND SYSTEMS,” the entirety of which is incorporated by reference herein. Referring to FIGS. 6B and 6E, one or more of the anchors (here atrial anchor 3202) can include double eyelet hooks 3224 positioned in the distal tip of the extension 3222a of the atrial anchor 3202. The eyelets 3224 advantageously allow tethers from the delivery device to hold the atrial loops in a retracted position. The outer radial positioning of the eyelets 3224 can advantageously allow the tethers to pull the loops tightly into the sheath. Further, the double eyelet hooks can advantageously make it easy for an operator to loop the tether therethrough (as shown in FIG. 6E).


Another embodiment of an eyelet 24 for delivery is shown in FIG. 7. Eyelet 24 is a full circle that allows a suture to be passed therethrough. The eyelets 24 are positioned at the peak or furthest radial position of the extensions 2422 on the atrial anchor 2402. The suture 2475 looping around the circumference of the anchor 2402 and through the eyelets 24 can help prevent the atrial anchor 2402 from flaring outwards during delivery.


In some embodiments, the eyelets can be only on the extensions of the atrial anchor. In other embodiments, the eyelets can be only or additionally on extensions of the ventricular anchor. As shown in FIGS. 6E and 7, the eyelets can be positioned along every other extension around the circumferential direction (such as only one of the overlapping frames, as shown in FIG. 7). In other embodiments, the eyelets can be positioned on every extension of the atrial or ventricular anchors.


The expandable anchors described herein can further include one or more apertures or holes configured for coupling attachment of various pieces of the valve. For example, referring to FIG. 6B, the expandable anchor 3201 can include a plurality of apertures 3246 therein configured to allow attachment via a coupler, such a rivet, to other sections of the valve, as described further below.


The prostheses herein also include struts or a strut frame, to which the replacement leaflets are attached for controlling blood flow through the valve. There can be three strut leaflets, which can form a pressure actuated valve that provides uni-directional flow occlusion when the prosthesis is implanted in the valve orifice. The leaflets can be constructed of bio-materials, such as bovine or porcine pericardium, or polymer materials.


Some central portions herein or other portions of other replacement heart valves may be susceptible to undesirable deforming when implanted, such as due to movement during the heartbeat and/or in response to pressures in the heart. The valves described herein can thus include a separate annular strut frame coupled to a radially inner portion of the central portion (i.e., within the central portion). The annular strut frame may distribute forces more evenly over the central portion of the expandable anchor and may reduce the likelihood of undesirable central portion deformation once implanted.


An annular strut frame is an additional layer of material secured to the radially inner portion of the central portion, which reinforces and stabilizes the central portion when implanted. Additionally, by creating a coupling between the struts and the central portion (as opposed to having a solid portion of material that can provide additional stability), the flexibility of the coupling allows for relative movement of the struts during collapse of the device. This can reduce stresses on the device as it is collapsed, allowing for a smaller delivery profile, which as discussed herein can be important for delivery, such as a transseptal approach. The term annular in this context does not require a perfect annulus.


When the prosthesis includes a strut frame, the struts can either be integral to the strut frame or they can be separate components that are secured to the strut frame during manufacturing.



FIG. 8 is a perspective view illustrating an exemplary annular strut frame 1000. Strut frame 1000 includes frame portion 1002 and plurality of struts 1004. Struts 1004 extend further distally (i.e., in the ventricular direction) than frame portion 1002, and are configured to be secured to replacement leaflets as described herein. The strut frame 1000 has a ventricular end 1006 and an atrial end 1008. Strut portion 1002 includes a plurality of arches, which define peaks 1012 and valleys 1014. In this embodiment there are six strut frame arches, with two between adjacent struts 1004. Struts 1004 have an arch configuration defined by first leg 1020 and second leg 1022, each of which has a plurality of suture apertures 1018 therein. Struts 1004 each also have first and second extensions 1024 and 1026 extending away from legs 1020 and 1022 and towards atrial end 1008. Extensions 1024 and 1026 may also be considered part of the frame portion rather than the struts. Replacement leaflets are secured to struts 1004 at holes 1018 (e.g., by suturing). The strut frame also includes a plurality of apertures 1010 near the atrial end 1008, which are used to secure the annular strut frame to the central portion of the expandable anchor. The apertures are located at valleys 1014 in the frame portion. In some embodiments the annular strut frame is positioned radially within the central portion so that each of apertures 1010 is aligned with an aperture in the central portion, such as apertures 36. A coupler (e.g., rivet) is then advanced through the aligned apertures and one side of the coupler is then plastically deformed to secure the annular strut frame to the central portion.



FIG. 9 illustrates an exemplary annular strut frame 1100. Strut frame 1100 includes three struts 1104 and frame portion 1102, which in this embodiment includes one arch between adjacent struts 1104. Unlike the embodiment in FIG. 8, in which there is one coupling aperture 1010 within each strut, in this embodiment there are two apertures 1110 within each strut 1104. Just as in the embodiment in FIG. 8, there are also apertures at the ends of each leg of struts. Strut frame 1100 is coupled to a central portion by aligning apertures 1110 with apertures in the central portion, such as aperture 36, and then extending a coupler through each set of aligned apertures, and plastically deforming each coupler to secure the central portion to the annular strut frame at the locations of the couplings.



FIGS. 8 and 9 illustrate exemplary strut frames in their expanded configurations, when the rest of the expandable anchor (e.g., ventricular anchor, central portion, and atrial anchor) is also in an expanded configuration. Strut frames 19 and 20 can be secured to, and considered part of, any of the expandable anchors herein.


In an exemplary method of manufacturing, the strut frame is cut from a tubular element, then expanded, and set in the expanded configuration using shape setting techniques described herein or otherwise known. For example, in an exemplary embodiment, the frame is cut from a 10 mm diameter tube, then expanded to an expanded configuration of about 32 mm (as shown in FIG. 19), and set in the expanded configuration. In some exemplary embodiments the strut frames herein are 0.25 mm to about 0.45 mm thick, such as about 0.35 mm thick.


The annular strut frame can be cut from a flat sheet and rolled up and secured together (examples of which are described above), or it can be cut from a tubular structure.



FIGS. 8 and 9 illustrate exemplary annular, or cylindrical, strut frames can be disposed radially within the central portion of the expandable anchor. The central portion and the strut frame can be thought of as creating a composite cylinder when they are coupled together. The composite cylinder is thicker than each of the central portion and strut frame individually. Each of the central portion and strut frame is, however, relatively thin and can flex with respect to the other component. The relative flexibility can make it easier to collapse into a delivery configuration. If the composite region were a single material with a thickness equivalent to the combined thickness of the central portion and strut frame, that modified region may not be able to collapse sufficiently to meet, for example, size constraints without overstraining. The central portion and strut frame acting as a composite structure will not overstrain when collapsed into a collapsed configuration since the central portion and strut frame can flex independently. The composite central portion and strut frame also, when the expandable anchor expands, has a thickness greater than each component individually, thus providing an increased thickness that may be needed to resist torqueing and other forces on the central portion when implanted. The composite central portion and cylindrical strut frame thus enables collapsing as needed without overstraining, as well as provides a thickness to the central region that resists torqueing and deformation due to forces acting on the expandable anchor when implanted.



FIGS. 10A-E illustrate another exemplary annular or cylindrical strut frame 2500 that can be disposed radially within the central portion of the expandable anchor. As shown, strut frame 2500 can include a frame portion 2502 at the atrial end 2508 and a plurality of struts 2504, such as three struts 2504, at the ventricular end 2506. While the frame portion 2502 can extend substantially around the entire valve, the struts 2504 can extend at discrete locations about the valve. For example, the midpoint or center of each of the struts 2504 can be positioned approximately 120° away from one another.


The entire frame 2500 can be made of a plurality of substantially diamond-shaped sub-features 2551 arranged in a pattern. The diamond sub-features 2551 can advantageously provide structural support to the strut frame 2500 and can be substantially resistant to deformation when circumferential and/or axial forces are placed on the strut frame 2500.


The atrial-most tips 2553 of the strut frame 2500 can be rounded or blunt to prevent damage to the tissue when implanted. Moreover, as shown in FIGS. 10A-D, the atrial tips 2553 of the strut frame can be flared radially outwards relative to the rest of the strut frame 2500, which can remain substantially cylindrical. The angle of the bend can be between 25 degrees and 30 degrees relative to a plane of the annulus (i.e., 60-65 degrees relative to the central vertical axis of the annulus). Further, the atrial trips can substantially conform to the angle of the atrial anchor relative to the central portion. A similarly flared structure can be seen in the strut frame 2415 of FIG. 7.


Referring still to FIGS. 10A-10D, the struts 2504 can each be substantially triangular in shape with blunt tips formed from three substantially aligned diamond sub-features (labeled as 2551a,b,c,d on FIG. 25B). The middle diamond sub-feature 2551b of each strut 2504 can include one or more eyelets 2555 formed as a sewing attachment point for the leaflets. Likewise, one or more of the diamond sub-features 2551 can include eyelets 2557 for attachment of the leaflets.


The strut frame 2500 can further include apertures 2510 that can be used as rivet holes for attachment to the anchor frame. The apertures 2510 can be positioned, for example, between the proximal-most diamond sub-features 2551 of the strut frame 2500.



FIG. 10D shows the same strut frame 2500 in a two-dimensional un-stretched configuration. To form the strut frame 2500 in the three-dimensional configuration shown in FIGS. 25A-25D, the two-dimensional version can be stretched linearly (in the direction shown by the arrows on FIG. 30), and the atrial end 2408 can be bent. Advantageously, the strut frame 2500 can be cut out of a single piece of material, such as a tube or a flat sheet. The strut frame 2500 can be approximately 12-15 mm high and 27-32 mm in diameter.


Referring to FIGS. 11A-B, the radial flare of the tips 2633 at the atrial end 2608 of the strut frame 2615 can allow the atrial end 2608 to sit substantially flush with the atrial anchor 2602. The tips 2633, however, can remain unattached to the atrial anchor 2602 in order to allow for ease of collapse.


In some embodiments, as shown best in FIG. 12A, the atrial tips 3133 of the strut frame 3100 can be axially aligned with the extensions 3122 of the atrial anchor 3102. That is, the midline of each tip 3133 can align with the midline of each extension 3122. The strut frame 3100 can be attached to the anchor 3100, such as a rivet extending between apertures 2510 (see FIGS. 10A-10D) and apertures formed in the central portion of the anchor. Further, as shown in FIG. 12B, the atrial tips 3133 substantially conform to the angle of the atrial anchor 3102, forming a continuous or smooth funnel from the proximal end to the distal end. The smooth funnel can advantageously ensure that blood flowing therethrough will flow continuously without catching or pooling within portions of the device, thereby preventing the formation of blood clots. Moreover, as further shown in FIG. 12B, the strut frame 3100 can be positioned such substantially all of the struts 3104 extend distally past the ventricular anchor 3104.


Another embodiment of a strut frame 3215 is shown in FIG. 6D. As shown in FIG. 6D, the strut frame 3215 includes a substantially cylindrical ventricular portion 3251 and a flared atrial portion 3253 extending at least partially radially away from the cylindrical ventricular portion 3251. The flared atrial portion forms an angle of approximately 25-30 degrees relative to a plane of the annulus (i.e., 60-65 degrees relative to the central vertical or longitudinal axis of the annulus). Further, in this embodiment, the atrial tips 3255 of the flared atrial portion curve back to point substantially in the axial direction (similar to the atrial anchor 3201). Thus, referring to FIG. 6A, when placed within the atrial anchor 3201, the flares and atrial tips of each will be substantially flush with one another.


Referring to FIG. 6D, the strut frame 3205 includes a plurality of zig-zag circumferential members extending around the circumference of the frame and a plurality of linear members extending from the ventricular end to the atrial end. Further, a plurality of eyelet apertures 3257 are positioned at the ventricular side. The eyelet apertures can be used to connect the strut frame 3215 to the anchor assembly 3201, such as via couplers or rivets.


In some embodiments, the strut frame 3205 can include a suture woven circumferentially around the strut frame 3205 (such as through the zig-zag members), similar to as shown in FIG. 7. The suture can advantageously help maintain the shape of the strut frame 3205 during delivery (e.g., help prevent flaring) so as to maintain low stress on the leaflets during delivery.


As shown in FIG. 6D, the strut frame 3215 further includes ovoid attachment features 3205 at the ventricular end of the frame 3215 (attached leaflets 3320 are shown in FIG. 6A). The ovoid attachment features 3205 include a plurality of sutures holes therein for attachment of the leaflets. The ovoid shape can advantageously distribute stress evenly at the highest stress point of the leaflets. In one embodiment, there can be three ovoid attachment features 3205 separated approximately 120 degrees around the circumference from one another. In this embodiment, other portions of the leaflets can be sewn directly to the zig-zag and/or features of the strut frame.


Another mechanism for attaching leaflets is shown in FIGS. 13A-13B. Strut frame 4615 includes one or more eyelets 4655 extending along the strut frame for sewing attachment of the leaflets 4620.


The strut frames described herein can be configured to mechanically isolate the leaflets from the anchoring mechanism of the implant, thereby isolating the leaflets from stresses caused by movement of the annulus and/or the non-uniform shape of the annulus. In any of the embodiments described herein, the strut frame can have greater radial strength or rigidity than the anchor, thereby allowing the strut frame to retain its substantially cylindrical shape while the anchor conforms to surrounding anatomy. In one embodiment, the strut frame deflection under full pressure loading results in a 1-2 mm decrease in diameter.


In some embodiments, a central member or suspension can extend between the strut frame and the anchor frame. The central member can help provide further mechanical isolation of the leaflets relative to the anchoring members. That is, it is generally desirable that the strut frame to which the leaflets are attached maintain its intended expanded configuration. If the strut frame deforms too extensively, the orientation and/or alignment of the replacement leaflets that are secured to the strut frame can be compromised, which may prevent proper leaflet coaptation during use. The central member described herein prevents or at least minimizes movement or deformation of the expandable anchor from being translated to the strut frame. Alternatively stated, the central member reduces deformation of the strut frame in response to deformation of the expandable anchor. The central member can thus be thought of as a shock system between the expandable anchor and the strut frame (or the replacement leaflets). In response to deformation of expandable anchor, the central member is configured to deform while preventing or minimizing deformation of the strut frame.



FIG. 14 illustrates a mitral valve prosthesis 300 (viewed from a ventricular side) that includes a central member 306 in addition to the expandable anchor 302 and strut frame 304. The expandable anchor 302 is coupled to the central member 306, and the central member 306 is coupled to strut frame 304. Strut frame 304 defines central opening 310. Although shown as including non-overlapping pear-shaped petals or extensions, the expandable anchor 302 can be any of the expandable anchors described above or incorporated by reference herein. Further, strut frame 304 can be any of the strut frames described above. Moreover, in some alternative embodiments, the strut frame shown in FIG. 14 is replaced with discrete struts. The replacement leaflets that are secured to strut frame 304 are not shown in FIG. 14 for clarity.


As shown in FIG. 14, the central member 306 can include a plurality of connectors or spring elements 308 extending between the anchor 302 and the strut frame 308. The spring elements 308 can be resilient members that together act as a suspension for the strut frame 304 and can compress or extend when force is applied thereto, but can return to their former shape when released. The spring elements 308 can thus be used to absorb forces placed on the anchoring member to prevent or reduce forces on the strut frame (and thus the leaflets). The spring elements 308 can include leaflet springs (as shown in FIG. 14), S-springs (as shown in FIG. 15A), V-springs (as shown in FIG. 15B, circle springs (as shown in FIG. 15C), or any other type of spring elements, such as helical springs. In some embodiments, all of the spring elements 308 are the same type of spring, while in other embodiments, different types of springs can be used.


In the exemplary embodiment in FIG. 14, central member 306 includes eighteen individual or discrete spring elements 308. The spring elements 308 are secured to expandable anchor 302 at a radially outer end and to strut frame 304 at a radially inner end. Springs 308 can be secured to expandable anchor 302 and to strut frame 304, for example, via rivets, such as is described herein. As shown, in FIGS. 15A-15C each spring element 308 can include two apertures 3912 therein at opposite ends of the spring. The apertures 3912 can allow for attachment of the spring elements 308 to the strut frame and the anchor through rivets or other attachment mechanisms. The spring elements 308 can be secured to expandable anchor 302 along the central portion of expandable anchor 302, which is the radially innermost portion of expandable anchor 302.


In other embodiments, there may be few or more spring elements 308. For example, if the expandable anchor had a design different than shown in FIG. 14, fewer spring elements 308 may be needed. Or, alternatively, the design in FIG. 14 could have nine spring elements 308, leaving out every other spring element around the strut frame 304. Alternatively, the implant can have four spring elements 308 disposed about every 90 degrees around the strut frame 304, or three spring elements 308, or even two spring elements 308. The implant can have, for example, inclusively, between 1 and 25 springs, such as between 1 and 20 spring elements, such as between 2 and 20 spring elements. In some embodiments, different spring elements 308 of the suspension 306 can have different spring constants. The spring constants can be between 20 g/mm and 100 g/mm.



FIGS. 16A-C show a mitral valve prosthesis 2800 including an outer expandable frame 2804, a central member 2806 (in the form of a plurality of individual spring elements), an annular strut frame 2802, and leaflets. As can be seen in FIGS. 16A-16C, the radially inner strut frame 2804 is radially offset from the outer expandable frame 2802 due to the central member or 2806.


In some embodiments, the central member can have a continuous annular configuration, such as form a continuous spring 2908, as shown in FIG. 15D, configured to extend around the entire circumference of the strut frame 304 (i.e., between the strut frame 304 and the anchor 302). The continuous spring can have a plurality of bends that act as springs and a plurality of apertures 2911, 2933 arranged in an alternating configuration such that neighboring apertures 2911, 2933 attach to the strut frame and the anchor assembly. As shown in FIG. 15D, the continuous spring can be attached such that at least one bed extends between the strut frame and the anchor frame, providing an offset (and additional spring element) between the two.



FIG. 6C similarly shows a central member 3206 having a continuous annular configuration. The central member 3206 includes a plurality of linear posts 3261 extending from the atrial end to the ventricular end and a plurality of zig-zag circumferential members 3266. The ventricular end of the central member 3206 has a smaller diameter (which can be, e.g., 25-30 mm, such as 27 mm) than the diameter of the atrial end (which can be e.g., 30-35 mm, such as 32 mm). Each post 3261 inches a ventricular eyelet or aperture 3236 and an atrial eyelet or aperture 3265. The apertures ventricular 3236 can be configured to connect with apertures 3257 on the strut frame while the atrial apertures 3265 can be configured to connect to apertures 3246 on the anchor assembly 3201. The central member 3206 thus angles inward from the anchor assembly 3201 to the strut frame 3215 so as to connect the two. As shown in FIG. 6A, the central member 3206 can connect the anchor assembly 3201 with the strut frame 3215 and can act as a suspension to allow relative movement between the two.



FIGS. 17A-D show a valve prosthesis 1700 with anchor assembly 1701 that is similar to the prosthesis of FIGS. 6A-6F, but three of the linear posts 1761 of the central member 1706 extend further in the ventricular direction than the rest, and sutures holes on the ovoid leaflet attachment mechanism 1705 are moved further proximally, thereby ensuring that the riveting attachment of the central member 1706 to the strut frame 1715 does not interfere with the attachment of the leaflets to the strut frame 1715.


The expandable anchor, central member or suspension, and strut frame optionally have different spring constants, which is generally a measure of how stiff and strong a material is. For example, the strut frame can have the greatest spring constant, while the central member or suspension can have the lowest spring constant to allow it be deformed most easily. The expandable anchor can have a spring constant in between that of the strut frame and central member. Strut frame can have the greatest spring constant to resist deformation as much as possible.


The central members described herein advantageously prevent or minimize torqueing or twisting of the strut frame in response to torqueing of the expandable anchor. Further, the central member can allow for radial movement while preventing or minimizing axial movement. For example, the elements (e.g., linear posts or individual suspension members) connecting the strut frame to the expandable anchor may have cross sections that are thin in the radial direction and thick in the axial and rotational directions. In some embodiments, the central member can help maintain the axial position of the components (strut frame and anchor) during packaging.


Since there are mitral valve anatomical differences between patients, the central members described herein can allow the prosthesis to be implanted in patients with varying anatomies and accommodate for those differences while preventing the strut frame from deforming too extensively. For example, the mitral valve can be dilated quite extensively in some patients, and thus there may be a desire to have some variability built into the prosthesis. The elements of the central member can compensate for that variability. For example, the same strut frame size can be used with anchors of inner and outer diameters, and the central member can compensate for the dimensional difference. For example, a strut frame having a diameter of 27 mm can be used in an anchor having a diameter of 32-38 mm. Likewise, a strut frame of 29 mm can be used with an anchor have a diameter of 38-44 mm in diameter. The spring length can be increased to support the valve as the anchor diameter increases. Further, the skirt can be configured to cover the gap between the anchor frame and the strut frame.


In some embodiments, the anchor assembly and/or the strut assembly can have integrated suspension units attached thereto. For example, referring to FIGS. 18A-18C, the valve 1800 includes strut frame 1815 and anchor assembly 1801. As shown in FIGS. 18A and 189B, the linear posts 1818 of the strut frame 1815 extend past the circumferential zig-zag features 1822 of the strut frame 1815 on the atrial side. Further, the posts each include eyelet holes 1820 at the atrial end thereof. The eyelet holes 1820 are configured to line up with eyelet holes 1857 (see FIG. 18C) on the atrial tips of the anchor assembly 1801 to provide for coupling attachment, such as through rivets. The atrial anchor in this embodiment has petals of alternating lengths (as best shown in FIG. 18C), so the extensions of the posts 1818 have alternating lengths to accommodate (as best shown in FIG. 18B). Similar to other embodiments described herein, the atrial side of the strut frame 1806 can flare outwards (see FIG. 18A). The posts 1818 can thus be used to attach the strut frame 1815 to the anchor assembly 1801. Further, because the posts 1801 have extensions in the atrial direction, those extensions can act as springs, such as leaf springs, to provide a suspensions between the main body of the strut frame 1815 and the anchor assembly 1801.


Another example of a valve 1900 with an integrated assembly is shown in FIGS. 19A-19C. In this embodiment, the posts 1918 are attached to the central portion of the anchor assembly 1901 rather than to the atrial petals. Because the posts 1918 are attached to the central portion (thereby providing suspension), the atrial petals of the atrial anchor 1902 can be more flexible, and overlapping petals can be used (as shown in FIG. 19A). Another valve assembly 3700 with the strut frame 3715 attached to the atrial anchor 3703 is shown in FIGS. 20A-20C. That is, the atrial anchor 3702 can include apertures 3710 (see FIG. 20C) configured to attach to apertures 3780 (see FIG. 20B) of the strut frame 3715. The alignment of the anchor 3701 and the strut frame 3715 is shown in FIG. 20A. The valves 1900 and 2700 thus include suspensions characteristics that are provided by offsetting the rivet attachment points towards the atrial side, thereby creating a cantilever beam supporting the leaflet strut coming from the atrium.


Any of the embodiments described hereinabove can further include hooks configured to enhance attachment of the implant to the tissue.


In one embodiment, as shown in FIG. 20C, the hooks 3732 can be positioned in the valleys between extensions 3722 of the ventricular anchor 3704, i.e., can extend from the radial inner-most part of the ventricular anchor 3204. In some embodiments, the hooks 3632 can additionally or alternatively be positioned in the valleys between extensions of the atrial anchor. Advantageously, by placing the hooks in the valley between the extensions, they do not drag on tissue during release and/or repositioning of the device. That is, by being positioned at the inner-most radial position, the hooks will not grab tissue until the atrial and ventricular anchors 3702, 3704 are fully or substantially fully deployed. Moreover, by having the hooks close to the central portion 3603, they will better grab onto meaty tissue of the annulus.


In another embodiment, as shown in FIGS. 6B and 6E, hooks 3232b can extend from the central portion 3203, such as point in radially outwards and/or slightly in the ventricular direction. Hooks 3222a can also extend from the ventricular anchor in the valleys and point substantially in the atrial direction.


The hooks can be configured to embed into annulus tissue, thereby helping to resist the pressure build-up on the ventricular side of the aorta.


When two components are secured together during manufacturing, they are considered to be non-integral, or non-monolithic, components. Different portions of the expandable anchor that are made from the same starting material are considered to be integral, or monolithic. For example, the ventricular anchor, central anchor, and atrial anchor can all be made from the same piece, i.e., be integral with one another. In contrast, a manufacturing step could include cutting a strut and an expandable anchor from different pieces of starting material, and securing them together, and they would be considered non-integral. In some embodiments, when one or more components are secured together, the coupling of the two components can be made so that the two components are rigidly secured at the coupling, or so that the two components can move to some degree at the location of the coupling of the two components (e.g., pivotable).


Rivets as used herein are an example of a coupler, as that term or derivatives thereof is used herein. The locations where components are secured to one another may be referred to as a coupling herein. Coupling also refers to the two components that are secured together. Riveting as used herein is an example of a method that plastically deforms a coupler to secure two or more components together at a coupling.


The rivets can be inserted through the apertures described herein and the ends can then be plastically deformed using known riveting techniques to secure the two or more components together. The rivets can be made of a suitable implantable material, such as platinum, platinum-iridium alloy, tantalum, nickel-titanium alloy, or titanium and titanium alloys, such as titanium 6-4eli. In some embodiments, the riveted coupling can be such that one or more rivets are not tightened all the way down to the secured components, which allows for hinging of the coupling, if desired. Rivets used for hinging may be made of materials suitable for implantable bearing surfaces such as Nitronic 60 alloy, or nitinol. Hinge pins can be coated with low-friction, high-durability coatings, such as diamond-like coating, or titanium nitride.


Use of rivets and hinges (as opposed to, for example, crimp tubes) can provide an additional benefit of preventing cracking that can occur as single pieces of material flex and move. Additionally, rivets and hinges can provide various degrees of relevant movement between portions of the valve, which can allow the valve to be collapsed into a smaller delivery profile for delivery. The relative movement can also provide increased flexibility of the valve during delivery. Rivets can also allow for a variation in the relative orientation of the riveted components. In some embodiments, rivets provide increased flexibility that allows for greater trackability during delivery and better self-centering of the anchor against cardiac tissue (i.e., provides advantages for both access and conformability to the anatomy).


The couplings herein (e.g., riveting) also allow different section of material with different physical properties to be secured to one another. This allows different sections of the expandable anchor to have different properties (e.g., stiffness) than other sections, as may be needed based on, for example, anatomical requirements. For example, atrial anchors can be made thinner than the central portion and/or ventricular anchors.


Coupling and rivets are described further in U.S. patent application Ser. No. 14/677,334, filed Apr. 2, 2015, titled “REPLACEMENT CARDIAC VALVES AND METHODS OF USE AND MANUFACTURE,” the entire contents of which are incorporated by reference herein.


Any of the valve prostheses described herein can include a fabric cover and/or skirt or one or more portions of the device. For example, FIG. 6A shows a skirt covering the anchor assembly.


In some embodiments, the valve prostheses have been shown without leaflets for clarity. It is to be understood that each of the embodiments described herein can included replacement leaflets attached thereto.


Any of the valve features or structural details of any device embodiment described herein can be incorporated or combined with any of the other embodiments herein. For example, the central members or suspensions described herein are not limited in use with the expandable anchors and strut frames in the specific embodiment, but can be replaced with any of the features described in any other embodiment.


In use, when the devices described herein can be used as mitral valve replacements. In some embodiments, when the replacement heart valve has been delivered near the mitral valve, the ventricular anchor can be deployed first in a cardiac chamber, such as the ventricle, and retracted to a seated position against the valve orifice, such as the mitral valve orifice. Then the center portion and atrial anchor portion may be deployed in another cardiac chamber, such as the atrium, wherein the expansion and reconfiguration of the atrial anchor and the central portion sandwiches the valve orifice securely between the anchors that have been deployed on either side of the annulus. Other exemplary aspects of the methods of delivery described in U.S. Pat. No. 8,870,948, issued Oct. 28, 2014, and in International Patent Application filed May 13, 2016, titled “CARDIAC VALVE DELIVERY DEVICES AND SYSTEMS,” both of which are incorporated by reference in their entireties.


When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.


Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.


Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.


Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.


Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.


As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical range recited herein is intended to include all sub-ranges subsumed therein.


Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.


The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.

Claims
  • 1. A system comprising: a prosthetic mitral valve configured to expand from a collapsed configuration to an expanded configuration and including:an anchor assembly comprising an atrial anchor, a ventricular anchor, and a central portion therebetween, in the expanded configuration, the atrial anchor extends radially outwards relative to the central portion and includes a plurality of extensions,an annular strut frame disposed radially within the anchor assembly and attached thereto, anda plurality of replacement leaflets secured to the annular strut frame, wherein at least one of the plurality of extensions includes an eyelet having a hook therein for attaching tether thereto for delivery of the prosthetic mitral valve; anda tether for attaching to the hook of the prosthetic mitral valve for delivery of the prosthetic mitral valve.
  • 2. The system of claim 1, wherein the annular strut frame is attached to the anchor assembly in the collapsed configuration.
  • 3. The system of claim 1, wherein the prosthetic mitral valve is configured to self-expand from the collapsed configuration to the expanded configuration.
  • 4. The system of claim 1, wherein the strut frame includes a plurality of linear posts and a plurality of circumferential zig-zag features extending therearound.
  • 5. The system of claim 1, wherein in the expanded configuration, the ventricular anchor extends outward from the central portion.
  • 6. The system of claim 5, wherein the anchor assembly forms an hour-glass shape.
  • 7. The system of claim 1, wherein the hooks are positioned on every other extension around the circumferential direction of the anchor assembly.
  • 8. The system of claim 1, wherein the anchor assembly includes a plurality of hooks extending from the central portion, the hooks configured to engage tissue.
  • 9. The system of claim 1, wherein each hook is in the form of a double eyelet hook.
  • 10. The system of claim 1, wherein the atrial and ventricular anchors are configured to compress native cardiac tissue proximate to a mitral valve orifice therebetween.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/688,673, filed Aug. 28, 2017, which is a continuation of U.S. patent application Ser. No. 15/669,805, filed Aug. 4, 2017, and titled “REPLACEMENT MITRAL VALVES,” now U.S. Pat. No. 10,143,552, which is a continuation of International Patent Application No. PCT/US2016/032550, filed May 13, 2016, titled “REPLACEMENT MITRAL VALVES,” now International Publication No. WO 2016/183526, which claims priority to U.S. Provisional Application No. 62/161,743, titled “REPLACEMENT MITRAL VALVES,” and filed May 14, 2015, and to U.S. Provisional Patent Application No. 62/259,565, titled “REPLACEMENT MITRAL VALVES,” and filed Nov. 24, 2015, the entireties of which is incorporated by reference herein. This application may be related to U.S. patent application Ser. No. 14/170,388, filed Jan. 31, 2014, titled “SYSTEM AND METHOD FOR CARDIAC VALVE REPAIR AND REPLACEMENT,” now U.S. Pat. No. 8,870,948, and U.S. patent application Ser. No. 14/677,320, filed Apr. 2, 2015, titled “REPLACEMENT CARDIAC VALVES AND METHODS OF USE AND MANUFACTURE,” the entireties of which are incorporated by reference herein. All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

US Referenced Citations (713)
Number Name Date Kind
3334629 Cohn Aug 1967 A
3409013 Berry Nov 1968 A
3540431 Mobin-Ubdin Nov 1970 A
3628535 Ostrowsky et al. Dec 1971 A
3642004 Osthagen et al. Feb 1972 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3795246 Sturgeon Mar 1974 A
3839741 Haller Oct 1974 A
3868956 Alfidi et al. Mar 1975 A
3874388 King et al. Apr 1975 A
4056854 Boretos et al. Nov 1977 A
4106129 Carpentier et al. Aug 1978 A
4233690 Akins Nov 1980 A
4291420 Reul Sep 1981 A
4326306 Poler Apr 1982 A
4425908 Simon Jan 1984 A
4501030 Lane Feb 1985 A
4531943 Van Tassel et al. Jul 1985 A
4580568 Gianturco Apr 1986 A
4602911 Ahmadi et al. Jul 1986 A
4610688 Silvestrini et al. Sep 1986 A
4617932 Kornberg Oct 1986 A
4648881 Carpentier et al. Mar 1987 A
4655218 Kulik et al. Apr 1987 A
4655771 Wallsten Apr 1987 A
4662885 DiPisa, Jr. May 1987 A
4665906 Jervis May 1987 A
4710192 Liotta et al. Dec 1987 A
4733665 Palmaz Mar 1988 A
4755181 Igoe Jul 1988 A
4796629 Grayzel Jan 1989 A
4819751 Shimada et al. Apr 1989 A
4834755 Silvestrini et al. May 1989 A
4856516 Hillstead Aug 1989 A
4865600 Carpentier et al. Sep 1989 A
4872874 Taheri Oct 1989 A
4873978 Ginsburg Oct 1989 A
4909252 Goldberger Mar 1990 A
4917102 Miller et al. Apr 1990 A
4927426 Dretler May 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5002556 Ishida et al. Mar 1991 A
5002559 Tower Mar 1991 A
5064435 Porter Nov 1991 A
5161547 Tower Nov 1992 A
5163953 Vince Nov 1992 A
5209741 Spaeth May 1993 A
5258023 Reger Nov 1993 A
5258042 Mehta Nov 1993 A
5332402 Teitelbaum Jul 1994 A
5336258 Quintero et al. Aug 1994 A
5350398 Pavcnik et al. Sep 1994 A
5370685 Stevens Dec 1994 A
5389106 Tower Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5405377 Cragg Apr 1995 A
5411552 Andersen et al. May 1995 A
5425762 Muller Jun 1995 A
5431676 Dubrul et al. Jul 1995 A
5443495 Buscemi et al. Aug 1995 A
5443499 Schmitt Aug 1995 A
5476506 Lunn Dec 1995 A
5476510 Eberhardt et al. Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5507767 Maeda et al. Apr 1996 A
5534007 St. Germain et al. Jul 1996 A
5545133 Burns et al. Aug 1996 A
5545211 An et al. Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554183 Nazar Sep 1996 A
5554185 Block et al. Sep 1996 A
5571215 Sterman et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5575818 Pinchuk Nov 1996 A
5645559 Hachtman et al. Jul 1997 A
5662671 Barbut et al. Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5693083 Baker et al. Dec 1997 A
5695498 Tower Dec 1997 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson, IV et al. Feb 1998 A
5720391 Dohm et al. Feb 1998 A
5725552 Kotula et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5735842 Krueger et al. Apr 1998 A
5769812 Stevens et al. Jun 1998 A
5807405 Vanney et al. Sep 1998 A
5817126 Imran Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824043 Cottone, Jr. Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5824055 Spiridigliozzi et al. Oct 1998 A
5824056 Rosenberg Oct 1998 A
5824064 Taheri Oct 1998 A
5843158 Lenker et al. Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5860966 Tower Jan 1999 A
5861024 Rashidi Jan 1999 A
5861028 Angell Jan 1999 A
5868783 Tower Feb 1999 A
5876448 Thompson et al. Mar 1999 A
5885228 Rosenman et al. Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5891191 Stinson Apr 1999 A
5895399 Barbut et al. Apr 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5944738 Amplatz et al. Aug 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5957973 Quiachon et al. Sep 1999 A
5968070 Bley et al. Oct 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5984959 Robertson et al. Nov 1999 A
5984973 Girard et al. Nov 1999 A
5993469 McKenzie et al. Nov 1999 A
5997557 Barbut et al. Dec 1999 A
6010522 Barbut et al. Jan 2000 A
6022370 Tower Feb 2000 A
6027525 Suh et al. Feb 2000 A
6042598 Tsugita et al. Mar 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6093203 Uflacker Jul 2000 A
6113612 Swanson et al. Sep 2000 A
6123723 Konya et al. Sep 2000 A
6142987 Fsugita Nov 2000 A
6162245 Jayaraman Dec 2000 A
6165209 Patterson et al. Dec 2000 A
6168579 Tsugita Jan 2001 B1
6171327 Daniel et al. Jan 2001 B1
6174322 Schneidt Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6187016 Hedges et al. Feb 2001 B1
6197053 Cosgrove et al. Mar 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6214036 Letendre et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6231544 Tsugita et al. May 2001 B1
6231551 Barbut May 2001 B1
6241757 An et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6251135 Stinson et al. Jun 2001 B1
6258114 Konya et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6277555 Duran et al. Aug 2001 B1
6309417 Spence et al. Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6319281 Patel Nov 2001 B1
6336934 Gilson et al. Jan 2002 B1
6336937 Vonesh et al. Jan 2002 B1
6338735 Stevens Jan 2002 B1
6348063 Yassour et al. Feb 2002 B1
6352708 Duran et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6379368 Corcoran et al. Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6416510 Altman et al. Jul 2002 B1
6419696 Ortiz et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440152 Gainor et al. Aug 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6475239 Campbell et al. Nov 2002 B1
6482228 Norred Nov 2002 B1
6485502 Don Michael et al. Nov 2002 B2
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6527800 McGuckin, Jr. et al. Mar 2003 B1
6540768 Diaz et al. Apr 2003 B1
6562058 Seguin et al. May 2003 B2
6592546 Barbut et al. Jul 2003 B1
6592614 Lenker et al. Jul 2003 B2
6610077 Hancock et al. Aug 2003 B1
6616675 Evard et al. Sep 2003 B1
6616682 Joergensen et al. Sep 2003 B2
6622604 Chouinard et al. Sep 2003 B1
6623518 Thompson et al. Sep 2003 B2
6635068 Dubrul et al. Oct 2003 B1
6635079 Unsworth et al. Oct 2003 B2
6652571 White et al. Nov 2003 B1
6656206 Corcoran et al. Dec 2003 B2
6663588 DuBois et al. Dec 2003 B2
6663663 Kim et al. Dec 2003 B2
6669724 Park et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673109 Cox Jan 2004 B2
6676668 Mercereau et al. Jan 2004 B2
6676692 Rabkin et al. Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6689144 Gerberding Feb 2004 B2
6689164 Seguin Feb 2004 B1
6692512 Jang Feb 2004 B2
6695864 Macoviak et al. Feb 2004 B2
6695865 Boyle et al. Feb 2004 B2
6702851 Chinn et al. Mar 2004 B1
6712836 Berg et al. Mar 2004 B1
6712842 Gifford, III et al. Mar 2004 B1
6712843 Elliott Mar 2004 B2
6723122 Yang et al. Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730377 Wang May 2004 B2
6733525 Yang et al. May 2004 B2
6752828 Thornton Jun 2004 B2
6758855 Fulton, III et al. Jul 2004 B2
6764503 Ishimaru Jul 2004 B1
6764509 Chinn et al. Jul 2004 B2
6767345 St. Germain et al. Jul 2004 B2
6773454 Wholey et al. Aug 2004 B2
6776791 Stallings et al. Aug 2004 B1
6790218 Jayaraman Sep 2004 B2
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6790237 Stinson Sep 2004 B2
6792979 Konya et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6821297 Snyders Nov 2004 B2
6837901 Rabkin et al. Jan 2005 B2
6843802 Villalobos et al. Jan 2005 B1
6849085 Marton Feb 2005 B2
6863668 Gillespie et al. Mar 2005 B2
6872223 Roberts et al. Mar 2005 B2
6872226 Cali et al. Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6881220 Edwin et al. Apr 2005 B2
6887266 Williams et al. May 2005 B2
6890340 Duane May 2005 B2
6893459 Macoviak May 2005 B1
6893460 Spenser et al. May 2005 B2
6905743 Chen et al. Jun 2005 B1
6908481 Cribier Jun 2005 B2
6911036 Douk et al. Jun 2005 B2
6911037 Gainor et al. Jun 2005 B2
6913614 Marino et al. Jul 2005 B2
6921397 Corcoran et al. Jul 2005 B2
6936058 Forde et al. Aug 2005 B2
6936067 Buchanan Aug 2005 B2
6945997 Huynh et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6953332 Kurk et al. Oct 2005 B1
6960220 Marino et al. Nov 2005 B2
6960224 Marino et al. Nov 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
6984242 Campbell et al. Jan 2006 B2
7011681 Vesely Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7025791 Levine et al. Apr 2006 B2
7037331 Mitelberg et al. May 2006 B2
7077861 Spence Jul 2006 B2
7087072 Marino et al. Aug 2006 B2
7115135 Corcoran et al. Oct 2006 B2
7122020 Mogul Oct 2006 B2
7144410 Marino et al. Dec 2006 B2
7166097 Barbut Jan 2007 B2
7175653 Gaber Feb 2007 B2
7175654 Bonsignore et al. Feb 2007 B2
7189258 Johnson et al. Mar 2007 B2
7191018 Gielen et al. Mar 2007 B2
7192435 Corcoran et al. Mar 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7235093 Gregorich Jun 2007 B2
7261732 Justino Aug 2007 B2
7320704 Lashinski et al. Jan 2008 B2
7329279 Haug et al. Feb 2008 B2
7374560 Ressemann et al. May 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7402171 Osborne et al. Jul 2008 B2
7413563 Corcoran et al. Aug 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7455689 Johnson Nov 2008 B2
7566336 Corcoran et al. Jul 2009 B2
7582104 Corcoran et al. Sep 2009 B2
7591848 Allen Sep 2009 B2
7625364 Corcoran et al. Dec 2009 B2
7632298 Hijlkema et al. Dec 2009 B2
7658748 Marino et al. Feb 2010 B2
7691115 Corcoran et al. Apr 2010 B2
7712606 Salahieh et al. May 2010 B2
7722666 Lafontaine May 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7749238 Corcoran et al. Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7803184 McGuckin, Jr. et al. Sep 2010 B2
7803186 Li et al. Sep 2010 B1
7824442 Salahieh et al. Nov 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7896915 Guyenot et al. Mar 2011 B2
7905901 Corcoran et al. Mar 2011 B2
7927351 Corcoran et al. Apr 2011 B2
7972361 Corcoran et al. Jul 2011 B2
8043368 Crabtree Oct 2011 B2
8057540 Letac et al. Nov 2011 B2
8092520 Quadri Jan 2012 B2
8167935 McGuckin, Jr. et al. May 2012 B2
8236049 Rowe et al. Aug 2012 B2
8317858 Straubinger et al. Nov 2012 B2
8366741 Chin et al. Feb 2013 B2
8398708 Meiri et al. Mar 2013 B2
8425593 Braido et al. Apr 2013 B2
8444689 Zhang May 2013 B2
8449599 Chau et al. May 2013 B2
8551132 Eskridge et al. Oct 2013 B2
8551161 Dolan Oct 2013 B2
8562672 Bonhoeffer et al. Oct 2013 B2
8568475 Nguyen et al. Oct 2013 B2
8579964 Lane et al. Nov 2013 B2
8579966 Seguin et al. Nov 2013 B2
8623074 Ryan Jan 2014 B2
8628566 Eberhardt et al. Jan 2014 B2
8673000 Tabor et al. Mar 2014 B2
8685080 White Apr 2014 B2
8721708 Seguin et al. May 2014 B2
8728155 Montorfano et al. May 2014 B2
8740962 Finch et al. Jun 2014 B2
8795356 Quadri et al. Aug 2014 B2
8801779 Seguin et al. Aug 2014 B2
8845722 Gabbay Sep 2014 B2
8852272 Gross et al. Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8894702 Quadri et al. Nov 2014 B2
8911455 Quadri et al. Dec 2014 B2
8956404 Bortlein et al. Feb 2015 B2
8986375 Garde et al. Mar 2015 B2
8998976 Gregg et al. Apr 2015 B2
9011527 Li et al. Apr 2015 B2
9017399 Gross et al. Apr 2015 B2
9023074 Theobald et al. May 2015 B2
9023100 Quadri et al. May 2015 B2
9034032 McLean et al. May 2015 B2
9039757 McLean et al. May 2015 B2
9060857 Nguyen et al. Jun 2015 B2
9101467 Eberhardt et al. Aug 2015 B2
9125740 Morriss et al. Sep 2015 B2
9132009 Hacohen et al. Sep 2015 B2
9155617 Carpentier et al. Oct 2015 B2
9168130 Straubinger et al. Oct 2015 B2
9168131 Yohanan et al. Oct 2015 B2
9232994 Miller Jan 2016 B2
9301836 Buchbinder et al. Apr 2016 B2
9387071 Tuval et al. Jul 2016 B2
9393110 Levi et al. Jul 2016 B2
9393112 Tuval et al. Jul 2016 B2
9414852 Gifford, III et al. Aug 2016 B2
9414913 Beith et al. Aug 2016 B2
9421083 Eidenschink et al. Aug 2016 B2
9421098 Gifford, III et al. Aug 2016 B2
9439757 Wallace et al. Sep 2016 B2
9474605 Rowe et al. Oct 2016 B2
9474609 Haverkost et al. Oct 2016 B2
9480556 Revuelta et al. Nov 2016 B2
9480558 Destefano Nov 2016 B2
9480563 Li Nov 2016 B2
9486306 Tegels et al. Nov 2016 B2
9492273 Wallace et al. Nov 2016 B2
9498330 Solem Nov 2016 B2
9498332 Hacohen et al. Nov 2016 B2
9504564 Nguyen et al. Nov 2016 B2
9504568 Ryan et al. Nov 2016 B2
9510943 Mesana et al. Dec 2016 B2
9554899 Granada et al. Jan 2017 B2
9561100 Pintor et al. Feb 2017 B2
9561103 Granada et al. Feb 2017 B2
9579198 Deem et al. Feb 2017 B2
9655722 Morriss et al. May 2017 B2
9788941 Hacohen Oct 2017 B2
9867697 Alkhatib et al. Jan 2018 B2
9883941 Hastings et al. Feb 2018 B2
9949824 Bonhoeffer et al. Apr 2018 B2
10004601 Tuval et al. Jun 2018 B2
10070954 Braido et al. Sep 2018 B2
10143552 Wallace et al. Dec 2018 B2
10179042 Braido et al. Jan 2019 B2
10231827 Mulvihill Mar 2019 B2
10299921 Dale et al. May 2019 B2
10376361 Gross et al. Aug 2019 B2
10433953 Wallace et al. Oct 2019 B2
10449047 Hariton et al. Oct 2019 B2
10470881 Noe et al. Nov 2019 B2
10624742 Granada et al. Apr 2020 B2
20010007956 Letac et al. Jul 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010041930 Globerman et al. Nov 2001 A1
20010044652 Moore Nov 2001 A1
20010044656 Williamson et al. Nov 2001 A1
20020002396 Fulkerson Jan 2002 A1
20020010489 Grayzel et al. Jan 2002 A1
20020026233 Shaknovich Feb 2002 A1
20020029981 Nigam Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020055769 Wang May 2002 A1
20020062135 Mazzocchi et al. May 2002 A1
20020082609 Green Jun 2002 A1
20020095173 Mazzocchi et al. Jul 2002 A1
20020120328 Pathak et al. Aug 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020177766 Mogul Nov 2002 A1
20020183781 Casey et al. Dec 2002 A1
20020188341 Elliott Dec 2002 A1
20020188344 Bolea et al. Dec 2002 A1
20030023303 Palmaz et al. Jan 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030040791 Oktay Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030060844 Borillo et al. Mar 2003 A1
20030070944 Nigam Apr 2003 A1
20030074011 Gilboa et al. Apr 2003 A1
20030109924 Cribier Jun 2003 A1
20030109930 Bluni et al. Jun 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030135257 Taheri Jul 2003 A1
20030144732 Cosgrove et al. Jul 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030149477 Gabbay Aug 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030212429 Keegan et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030216774 Larson Nov 2003 A1
20030225421 Peavey et al. Dec 2003 A1
20030225445 Derus et al. Dec 2003 A1
20030229390 Ashton et al. Dec 2003 A1
20030233117 Adams et al. Dec 2003 A1
20040034411 Quijano et al. Feb 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040049226 Keegan et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040060563 Rapacki et al. Apr 2004 A1
20040082904 Houde et al. Apr 2004 A1
20040082967 Broome et al. Apr 2004 A1
20040087982 Eskur May 2004 A1
20040093016 Root et al. May 2004 A1
20040098022 Barone May 2004 A1
20040098099 McCullagh et al. May 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040116951 Rosengart Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040127849 Kantor Jul 2004 A1
20040127936 Salahieh et al. Jul 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040133274 Webler et al. Jul 2004 A1
20040138694 Tran et al. Jul 2004 A1
20040143294 Corcoran et al. Jul 2004 A1
20040148021 Cartledge et al. Jul 2004 A1
20040153094 Dunfee et al. Aug 2004 A1
20040158277 Lowe et al. Aug 2004 A1
20040167565 Beulke et al. Aug 2004 A1
20040181140 Falwell et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040204755 Robin Oct 2004 A1
20040215331 Chew et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040220655 Swanson et al. Nov 2004 A1
20040225321 Krolik et al. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20050033402 Cully et al. Feb 2005 A1
20050038383 Kelley et al. Feb 2005 A1
20050070934 Tanaka et al. Mar 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050085841 Eversull et al. Apr 2005 A1
20050085842 Eversull et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050085890 Rasmussen et al. Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050096692 Linder et al. May 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050100580 Osborne et al. May 2005 A1
20050107822 WasDyke May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050165352 Henry et al. Jul 2005 A1
20050182486 Gabbay Aug 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050209580 Freyman Sep 2005 A1
20050228472 Case et al. Oct 2005 A1
20050251250 Verhoeven et al. Nov 2005 A1
20050251251 Cribier Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267560 Bates Dec 2005 A1
20050283962 Boudjemline Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060015168 Gunderson Jan 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060116717 Marino et al. Jun 2006 A1
20060155312 Levine et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060190030 To et al. Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060235510 Johnson et al. Oct 2006 A1
20060247680 Amplatz et al. Nov 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265045 Shiu et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060287668 Fawzi et al. Dec 2006 A1
20070016286 Herrmann et al. Jan 2007 A1
20070055340 Pryor Mar 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070100440 Figulla et al. May 2007 A1
20070112355 Salahieh et al. May 2007 A1
20070118214 Salahieh et al. May 2007 A1
20070203503 Salahieh et al. Aug 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070255389 Oberti et al. Nov 2007 A1
20070265656 Amplatz et al. Nov 2007 A1
20070276324 Laduca et al. Nov 2007 A1
20070288089 Gurskis et al. Dec 2007 A1
20080015619 Figulla et al. Jan 2008 A1
20080033543 Gurskis et al. Feb 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080140191 Mathis et al. Jun 2008 A1
20080167682 Corcoran et al. Jul 2008 A1
20080177381 Navia et al. Jul 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080234797 Styrc Sep 2008 A1
20080288054 Pulnev et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090036768 Seehusen et al. Feb 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090082803 Adams et al. Mar 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090182405 Arnault De La Menardiere et al. Jul 2009 A1
20090192585 Bloom et al. Jul 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090254165 Tabor et al. Oct 2009 A1
20090264759 Byrd Oct 2009 A1
20090287290 Macaulay et al. Nov 2009 A1
20090306768 Quadri Dec 2009 A1
20100036479 Hill et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100094314 Hernlund et al. Apr 2010 A1
20100114308 Maschke May 2010 A1
20100121434 Paul et al. May 2010 A1
20100161036 Pintor et al. Jun 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100219092 Salahieh et al. Sep 2010 A1
20100268204 Tieu et al. Oct 2010 A1
20100280495 Paul et al. Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20100312333 Navia et al. Dec 2010 A1
20110004296 Lutter et al. Jan 2011 A1
20110022157 Essinger et al. Jan 2011 A1
20110034987 Kennedy Feb 2011 A1
20110166636 Rowe Jul 2011 A1
20110218619 Benichou et al. Sep 2011 A1
20110245911 Quill et al. Oct 2011 A1
20110257723 McNamara Oct 2011 A1
20110264198 Murray, III et al. Oct 2011 A1
20110295363 Girard et al. Dec 2011 A1
20110301702 Rust et al. Dec 2011 A1
20120016464 Seguin Jan 2012 A1
20120022640 Gross et al. Jan 2012 A1
20120053685 Cerf et al. Mar 2012 A1
20120059458 Buchbinder et al. Mar 2012 A1
20120078347 Braido et al. Mar 2012 A1
20120078360 Rafiee Mar 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120158129 Duffy et al. Jun 2012 A1
20120197283 Marchand et al. Aug 2012 A1
20120197391 Alkhatib et al. Aug 2012 A1
20130041447 Erb et al. Feb 2013 A1
20130041458 Lashinski et al. Feb 2013 A1
20130253643 Rolando et al. Sep 2013 A1
20130261737 Costello Oct 2013 A1
20130282110 Schweich, Jr. et al. Oct 2013 A1
20130282114 Schweich, Jr. et al. Oct 2013 A1
20130304197 Buchbinder et al. Nov 2013 A1
20130304200 McLean et al. Nov 2013 A1
20130310923 Kheradvar et al. Nov 2013 A1
20130331931 Gregg et al. Dec 2013 A1
20140005771 Braido et al. Jan 2014 A1
20140005775 Alkhatib et al. Jan 2014 A1
20140005778 Buchbinder et al. Jan 2014 A1
20140012368 Sugimoto et al. Jan 2014 A1
20140012374 Rankin Jan 2014 A1
20140052237 Lane et al. Feb 2014 A1
20140052241 Harks et al. Feb 2014 A1
20140052244 Rolando et al. Feb 2014 A1
20140067048 Chau et al. Mar 2014 A1
20140081383 Eberhardt et al. Mar 2014 A1
20140107665 Shellenberger et al. Apr 2014 A1
20140114408 Dwork Apr 2014 A1
20140128726 Quill et al. May 2014 A1
20140180391 Dagan et al. Jun 2014 A1
20140194983 Kovalsky et al. Jul 2014 A1
20140214157 Bortlein et al. Jul 2014 A1
20140214159 Vidlund et al. Jul 2014 A1
20140222136 Geist et al. Aug 2014 A1
20140222142 Kovalsky et al. Aug 2014 A1
20140236278 Argentine et al. Aug 2014 A1
20140243954 Shannon Aug 2014 A1
20140249622 Carmi et al. Sep 2014 A1
20140257476 Montorfano et al. Sep 2014 A1
20140277390 Ratz et al. Sep 2014 A1
20140277563 White Sep 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140330368 Gloss et al. Nov 2014 A1
20140330370 Matheny et al. Nov 2014 A1
20140371844 Dale et al. Dec 2014 A1
20140379076 Vidlund et al. Dec 2014 A1
20150025623 Granada et al. Jan 2015 A1
20150039083 Rafiee Feb 2015 A1
20150045881 Lim Feb 2015 A1
20150066141 Braido et al. Mar 2015 A1
20150094802 Buchbinder et al. Apr 2015 A1
20150112430 Creaven et al. Apr 2015 A1
20150119637 Alvarez et al. Apr 2015 A1
20150135506 White May 2015 A1
20150142100 Morriss et al. May 2015 A1
20150157457 Hacohen Jun 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150223773 John et al. Aug 2015 A1
20150272737 Dale et al. Oct 2015 A1
20150302634 Florent et al. Oct 2015 A1
20150351903 Morriss et al. Dec 2015 A1
20150351904 Cooper et al. Dec 2015 A1
20160038280 Morriss et al. Feb 2016 A1
20160089234 Gifford, III Mar 2016 A1
20160151153 Sandstrom et al. Jun 2016 A1
20160158000 Granada et al. Jun 2016 A1
20160158003 Wallace et al. Jun 2016 A1
20160166384 Olson et al. Jun 2016 A1
20160235529 Ma et al. Aug 2016 A1
20160278922 Braido et al. Sep 2016 A1
20160310267 Zeng et al. Oct 2016 A1
20160310269 Braido et al. Oct 2016 A1
20170035569 Deem et al. Feb 2017 A1
20170042675 Freudenthal Feb 2017 A1
20170049571 Gifford, III Feb 2017 A1
20170056169 Johnson et al. Mar 2017 A1
20170128203 Zhang et al. May 2017 A1
20170209261 Bortlein et al. Jul 2017 A1
20170209269 Conklin Jul 2017 A1
20170231762 Quadri et al. Aug 2017 A1
20170245991 Granada et al. Aug 2017 A1
20170325941 Wallace et al. Nov 2017 A1
20170325948 Wallace et al. Nov 2017 A1
20170354499 Granada et al. Dec 2017 A1
20180000580 Wallace et al. Jan 2018 A1
20180056043 von Oepen et al. Mar 2018 A1
20180092744 von Oepen et al. Apr 2018 A1
20180110622 Gregg et al. Apr 2018 A1
20180206983 Noe et al. Jul 2018 A1
20180206984 Noe et al. Jul 2018 A1
20180206985 Noe et al. Jul 2018 A1
20180206986 Noe et al. Jul 2018 A1
20180256327 Perszyk et al. Sep 2018 A1
20180296325 McLean Oct 2018 A1
20180296335 Miyashiro Oct 2018 A1
20180296339 McLean Oct 2018 A1
20180296341 Noe et al. Oct 2018 A1
20180333259 Dibie Nov 2018 A1
20190201196 Granada et al. Jul 2019 A1
20200078167 Quijano et al. Mar 2020 A1
Foreign Referenced Citations (82)
Number Date Country
2018100602 Jun 2018 AU
2859666 Jun 2013 CA
1338951 Mar 2002 CN
102438546 May 2012 CN
104918583 Sep 2015 CN
205434001 Aug 2016 CN
0409929 Jan 1991 EP
0819013 Jan 1998 EP
0937439 Aug 1999 EP
1042045 Oct 2000 EP
1057459 Dec 2000 EP
1057460 Dec 2000 EP
1059894 Dec 2000 EP
1078610 Feb 2001 EP
1229864 Aug 2002 EP
1340473 Sep 2003 EP
1356793 Oct 2003 EP
1430853 Jun 2004 EP
1469797 Nov 2005 EP
1600121 Nov 2005 EP
1616531 Jan 2006 EP
1819304 Aug 2007 EP
1849440 Oct 2007 EP
2654624 Oct 2013 EP
2124826 Jul 2014 EP
2002536115 Oct 2002 JP
9504556 Feb 1995 WO
9529640 Nov 1995 WO
9614032 May 1996 WO
9624306 Aug 1996 WO
9836790 Aug 1998 WO
9857599 Dec 1998 WO
9944542 Sep 1999 WO
0009059 Feb 2000 WO
0044308 Aug 2000 WO
200044313 Aug 2000 WO
0067661 Nov 2000 WO
0105331 Jan 2001 WO
0135870 May 2001 WO
0164137 Sep 2001 WO
0236048 May 2002 WO
2002041789 May 2002 WO
02100297 Dec 2002 WO
2003003943 Jan 2003 WO
2003003949 Jan 2003 WO
03011195 Feb 2003 WO
03015851 Feb 2003 WO
2003030776 Apr 2003 WO
03094797 Nov 2003 WO
2004014256 Feb 2004 WO
2004019811 Mar 2004 WO
2004026117 Apr 2004 WO
2004041126 May 2004 WO
2004047681 Jun 2004 WO
2004066876 Aug 2004 WO
2004082536 Sep 2004 WO
2005037361 Apr 2005 WO
2005084595 Sep 2005 WO
2005087140 Sep 2005 WO
2009072122 Jun 2009 WO
2009108615 Sep 2009 WO
2009132187 Oct 2009 WO
2009137755 Nov 2009 WO
2010057262 May 2010 WO
2010141847 Dec 2010 WO
2011057087 May 2011 WO
2011081997 Jul 2011 WO
2012161786 Nov 2012 WO
2013158608 Oct 2013 WO
2013158613 Oct 2013 WO
2014121280 Aug 2014 WO
2014144247 Sep 2014 WO
2015127283 Aug 2015 WO
2016168609 Oct 2016 WO
2016183523 Nov 2016 WO
2016183526 Nov 2016 WO
2017035002 Mar 2017 WO
2017035434 Mar 2017 WO
2017122109 Jul 2017 WO
2017167759 Oct 2017 WO
2017218877 Dec 2017 WO
2019023385 Jan 2019 WO
Non-Patent Literature Citations (43)
Entry
International Search Report including the Written Opinion from Application No. PCT/US201 9/037729 dated Aug. 21, 2019, pp. 1-11.
Search Report from First Office Action for Chinese Application No. 201880020112.X dated May 6, 2021; 2 pages.
Australian Notice of Acceptance for Application No. AU 2018203053 dated Feb. 13, 2020, 3 pages.
Australian Examination Report for Application No. 2016262564 dated Feb. 19, 2020, 5 pages.
Andersen et al.; Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs; Euro. Heart J.; 13(5): 704-708; May 1992.
Atwood et al.; Insertion of Heart Valves by Catheterization; Project Supervised by Prof. S. Muftu of Northeastern University, May 2002: pp. 36-40.
Bodnar et al. Replacement Cardiac Valves; (Chapter 13) Extinct cardiac valve prostheses. Pergamon Publishing Corporation. New York, Aug. 1991: pp. 307-322.
Boudjemline et al. Percutaneous implantation of a biological valve in the aorta to treat aortic valve insufficiency—a sheep study.f Med Sci. Monit; Apr. 2002; vol. 8, No. 4: BR113-116.
Boudjemline et al. “Percutaneous implantation of a valve in the descending aorta in lambs.” Euro. Heart J; Jul. 2002; 23: 1045-1049.
Boudjemline et al. “Percutaneous pulmonary valve replacement in a large right ventricular outflow tract: an experimental study.” Journal of the American College of Cardiology; Mar. 2004; vol. 43(6): 1082-1087.
Boudjemline et al. “Percutaneous valve insertion: A new approach?” J. of Thoracic and Cardio. Surg; Mar. 2003; 125(3): 741-743.
Boudjemline et al. “Steps Toward Percutaneous Aortic Valve Replacement.” Circulation; Feb. 2002; 105: 775-778.
Cribier et al. “Early Experience with Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients with Calcific Aortic Stenosis.” J. of Am. Coli. of Cardio; Feb. 2004; 43(4): 698-703.
Cribier et al. “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case.” Percutaneous Valve Technologies, Inc. 2002: 16 pages (year of pub. sufficiently earlier than effective US filedand any foreign priority date).
Cribier et al. “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case.” (slide presentation); TCT 2002 (conference); 16 pgs.; Washington D.C.; Sep. 24-28, 2002.
Ferrari et al. “Percutaneous transvascular aortic valve replacement with self expanding stent-valve device.” Poster from the presentation given at SMIT 2000, 12th International Conference. 1 pg. Sep. 5, 2000.
Granada et al.; U.S. Appl. No. 16/224,221 entitled “System and method for cardiac valve repair and replacement,” filed Dec. 18, 2018.
Hijazi “Transcatheter Valve Replacement: A New Era of Percutaneous Cardiac Intervention Begins.” J. of Am. College of Cardia; Mar. 2004; 43(6): 1088-1089.
Huber et al. “Do valved stents compromise coronary flow?” European Journal of Cardio-thoracic Surgery; May 2004; vol. 25: 754-759.
Knudsen et al. “Catheter-implanted prosthetic heart valves.” Int'l J. of Art. Organs; May 1993; 16(5): 253-262.
Kort et al. “Minimally invasive aortic valve replacement: Echocardiographic and clinical results.” Am. Heart J; Sep. 2001; 142(3): 476-481.
Love et al. The Autogenous Tissue Heart Valve: Current Stat. Journal of Cardiac Surgery; Dec. 1991; 6(4): 199-507.
Lutter et al. “Percutaneous aortic valve replacement: An experimental study. I. Studies on implantation.” J. of Thoracic and Cardio. Surg; Apr. 2002; 123(4 ): 768-776.
Moulopoulos et al. “Catheter-Mounted Aortic Valves.” Annals of Thoracic Surg; May 1971; 11(5): 423-430.
Paniagua et al. “Percutaneous heart valve in the chronic in vitro testing model.” Circulation; Sep. 2002; 106: e51-e52.
Paniagua et al. Heart Watch (2004). Texas Heart Institute. Spring Mar. 2004 Edition: 8 pages.
Pavcnik et al. “Percutaneous bioprosthetic veno valve: A long-term study in sheep.” J. of Vascular Surg; Mar. 2002; 35(3): 598-603.
Phillips et al. “A Temporary Catheter-Tip Aortic Valve: Hemodynamic Effects on Experimental Acute Aortic nsufficiency.” Annals of Thoracic Surg; Feb. 1976; 21 (2): 134-136.
Sochman et al. “Percutaneous Transcatheter Aortic Disc Valve Prosthesis Implantation: A Feasibility Study.” Cardiovasc. Lntervent. Radiol; Sep.-Oct. 2000; 23: 384-388.
Solvay; Novel revivent(tm) Myocardial anchoring system from bioVentrix uses solvay's zeniva® PEEK in tether component; 3 pages retrieved from the internet (http://www.solvay.com/en/media/press_release/20131205⋅novel-revivent-myocardial-anchoring-system-bioventrix-uses-zenivapeek.html); (Press Release); on Aug. 10, 2017.
Stuart, M. “In Heart Valves, a Brave, New Non-Surgical World.” Start-Up; Feb. 2004: 9-17.
Vahanian et al. “Percutaneous Approaches to Valvular Disease.” Circulation; Apr. 2004; 109:1572-1579.
Van Herwerden et al., “Percutaneous valve implantation: back to the future?” Euro. Heart J; Sep. 2002; 23(18): 1415-1416.
Zhou et al. “Self-expandable valved stent of large size: off-bypass implantation in pulmonary position.” Eur. J. Cardiothorac; Aug. 2003; 24: 212-216.
Wallace et al., U.S. Appl. No. 16/310,499 entitled “Cardiac valve delivery devices and systems,” filed Dec. 17, 2018.
Gregg et al.; U.S. Appl. No. 15/573,555 entitled “Cardiac valve delivery devices and systems,” filed Nov. 13, 2017.
Noe et al.; U.S. Appl. No. 16/012,666 entitled “Replacement mitral valves,” filed Jun. 19, 2018.
Noe et al.; U.S. Appl. No. 15/909,610 entitled “Replacement mitral valves,” filed Mar. 1, 2018.
Noe et al.; U.S. Appl. No. 15/909,881 entitled “Replacement mitral valves,” filed Mar. 1, 2018.
Noe et al.; U.S. Appl. No. 15/910,484 entitled “Replacement mitral valves,” filed Mar. 2, 2018.
Noe et al.; U.S. Appl. No. 15/908,701 entitled “Replacement mitral valves,” filed Feb. 28, 2018.
Wallace et al.; U.S. Appl. No. 15/669,788 entitled “Replacement cardiac valves and methods of use and manufacture,” filed Aug. 4, 2017.
Granada et al.; U.S. Appl. No. 15/688,701 entitled “System and method for cardiac valve repair and replacement,” filed Aug. 28, 2017.
Related Publications (1)
Number Date Country
20200155308 A1 May 2020 US
Provisional Applications (2)
Number Date Country
62259565 Nov 2015 US
62161743 May 2015 US
Continuations (3)
Number Date Country
Parent 15688673 Aug 2017 US
Child 16734881 US
Parent 15669805 Aug 2017 US
Child 15688673 US
Parent PCT/US2016/032550 May 2016 US
Child 15669805 US